2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Hot Flashes
7
Head and Neck Neoplasms
7
Breast Neoplasms
7
Pain, Postoperative
4
Prostatic Neoplasms
3
Pain
3
Vomiting
2
Squamous Cell Carcinoma of Head and Neck
2
Oropharyngeal Neoplasms
2
Neuralgia
2
Neoplasms
2
Nausea
2
Mucositis
2
Depression
2
Anxiety Disorders
2
Agnosia
2
Acute Pain
2
Urinary Bladder Neoplasms
1
Stomatitis
1
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
1
Rectal Neoplasms
1
Psychotic Disorders
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neurotoxicity Syndromes
1
Myalgia
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Laryngeal Diseases
1
Ileus
1
Interventions
Sirolimus
4
LY3295668 erbumine
3
Everolimus
3
Medical Marijuana
2
Anticonvulsants
2
ziprasidone
1
perampanel
1
enzalutamide
1
clevidipine
1
brivaracetam
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Topotecan
1
Tobramycin
1
Therapeutic Touch
1
Temozolomide
1
TAS-119
1
Surgical Procedures, Operative
1
Sulfasalazine
1
Spironolactone
1
Sevoflurane
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Registries
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epilepsy
×
Gabapentin
×
Clear all
NCT05664464
2024-05-10
GLUGLIO
University of Zurich
Phase 1/2
Recruiting
120 enrolled